Drugs / DPX-RSV(A)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02472548 | May 2015 → Mar 2017 | respiratory syncytial virus infectious disease | Dalhousie University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DPX-RSV(A) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02472548 ↗ |
| Modality | Peptide | “Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.” NCT02472548 ↗ |
| Route | Intramuscular | “Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.” NCT02472548 ↗ |